Tags : Syncona

Series C

Freeline secures £96 million Series C investment led by Novo

Freeline Closes $120 Million Series C Financing Round Supported by leading international investors led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company – London, 30 June, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline […]Read More